• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Microbiome Times

Pharma & Human Health

Clinical Study Results Demonstrate Benefits of High-Potency, Multi-Strain Probiotic Formulations

March 25, 2019 Microbiome Times

Results from a clinical trial performed by Taverniti and colleagues from the University of Milan (IT) suggest that ingesting higher doses of multispecies probiotic formulations may permit higher, earlier and longer recovery of probiotics in […]

Pharma & Human Health

MTIG Position Statement on FMT Regulations

March 25, 2019 Microbiome Times

The Microbiome Therapeutics Innovation Group (MTIG) announced the publication of its Position Statement on Fecal Microbiota Transplantation (FMT) treatment. The statement supports the FDA Draft Guidance providing for patient access to FMT treatment through clinical […]

Pharma & Human Health

Enterome Announces Research Collaboration with Dana-Farber Cancer Institute Focused on New Microbiome-derived Cancer Immunotherapy

March 22, 2019 Microbiome Times

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics, has entered into a research and […]

Finance

Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca

March 11, 2019 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced a three-year research collaboration with AstraZeneca. The collaboration will focus on advancing mechanistic understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with […]

Finance

SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials

March 11, 2019 Microbiome Times

SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announced a $50 million series A financing led by existing investor Lundbeckfonden Emerge (Copenhagen) and LSP (Amsterdam), together with North-East […]

Finance

L’Oréal Announces Partnership With uBiome To Advance New Research Into The Skin Microbiome

March 11, 2019 Microbiome Times

L’Oréal announced a partnership between its Technology Incubator and Silicon Valley-based uBiome, the leader in microbial genomics, to continue its longtime research into skin microbiome—the trillions of bacteria that live on, and provide an important […]

Editor's Choice

Health for Life Capital II™, World Leading Microbiome-focused Fund Announces its First Close

March 5, 2019 Microbiome Times

Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, announces it has completed the first closing of its second dedicated fund focused on the microbiome, and health, […]

Finance

Kaleido Biosciences Announces Pricing of Initial Public Offering

March 1, 2019 Microbiome Times

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, announced the pricing of its initial […]

Phytobiome & Environment

Pivot Bio Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2019

February 28, 2019 Microbiome Times

Pivot Bio announced it is named to Fast Company’s annual list of the World’s Most Innovative Companies in 2019. The company was recognized for its transformational work in agriculture, earning Pivot Bio the eighth spot […]

Finance

Axial Biotherapeutics Raises $25 Million in Series B Financing

February 28, 2019 Microbiome Times

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative and neuropsychiatric diseases, today announced the completion of a $25 million series B equity financing. New investor Seventure Partners, […]

Pharma & Human Health

Acurx Announces First-In-Man Clinical Trial Data of ACX-362E for CDI

February 28, 2019 Microbiome Times

Acurx Pharmaceuticals, LLC (“Acurx” or the “Company”), a privately-held, clinical stage, biopharmaceutical company developing new antibiotics for difficult-to-treat bacterial infections, announced today that its lead product candidate, ACX-362E, has successfully completed the 32-subject, double-blinded, placebo-controlled, […]

Posts navigation

« 1 … 56 57 58 … 78 »

Download the MT Forum Agenda:

Sign Up to Free Newsletter

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    February 11, 2026
  • Immunity as a Lifestyle Priority
    January 30, 2026
  • Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
    November 17, 2025
  • The OMNIgene™•VAGINAL device – Optimized solutions for vaginal microbiome studies
    November 12, 2025
  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
sign up

Sign up to the Microbiome Times newsletter